ClinicalTrials.gg
CompletedNCT03482024Updated Mar 23, 2023Results posted

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

A Phase 1 interventional study of Tirzepatide in Renal Insufficiency and End Stage Renal Disease, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Primary conditionKidney Failure, ChronicRegistry: Renal InsufficiencyReclassifiedWhy we changed it
Registry
Renal Insufficiency — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
331st of 638
45 · median 48
Started
2018
with 39 others
Phase 1
89 of 765
8 open now
Registered
506th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 331st largest by enrollment of the 638 interventional ones that give a count, is one of 40 that started in 2018, is one of 89 in phase 1, and was the 506th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

03

Conditions studied

  • Renal Insufficiency
  • End Stage Renal Disease

Browse trials for

04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 45 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Participants:

    • Women not of may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or
    • Are between the (BMI) of 19.0 and 40.0 kilograms per meter squared (kg/m²), inclusive, at screening
  • Healthy Participants:

    -- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated (eGFR) ≥90 milliliters per minute (mL/min) at screening

  • Participants with Renal Impairment or ESRD:

    -- Males or females with stable mild to severe renal impairment, assessed by eGFR or with ESRD (having received hemodialysis for at least 3 months)

  • Participants with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment or ESRD:

    • Have T2DM controlled with diet or exercise alone or stable on metformin for at least 8 weeks
    • Taking stable doses of over-the-counter or prescription medications (eg, antihypertensive agents, aspirin, lipid-lowering agents) for treatment of concurrent medical conditions are permitted to participate providing they have been stable on their treatment regimen for at least 4 weeks
    • Have a (HbA1c) ≥7.0% and ≤11.0% at screening

Exclusion criteria

Exclusion Criteria:

  • All Participants:

    • Women of
    • Have known allergies to tirzepatide or related compounds
    • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
    • Have serum (AST) or alanine aminotransferase (ALT) >2× the (ULN) or total (TBL) >1.5× ULN
    • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
  • Participants with Renal Impairment or ESRD:

    • Have \<8.5 grams per deciliter (g/dL) or significant active hematological disease from causes other than underlying renal disease.
    • Have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before LY3298176 administration
  • Participants with T2DM and Renal Impairment or ESRD:

    • Have taken any glucose-lowering medications other than metformin, including insulin, in the past 3 months before screening
    • Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Tirzepatide - Control

    Group 1 - Tirzepatide 5 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide - Mild Renal Impairment

    Group 2 - Tirzepatide 5mg administered SC to participants with mild renal impairment.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide - Moderate Renal Impairment

    Group 3 - Tirzepatide 5mg administered SC to participants with moderate renal impairment.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide - Severe Renal Impairment

    Group 4 - Tirzepatide 5mg administered SC to participants with severe renal impairment.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide - End Stage Renal Disease (ESRD)

    Group 5 - Tirzepatide 5mg administered SC to participants with ESRD.

    Drug: Tirzepatide

Interventions

  • Administered SC.

    Also known as: LY3298176

07

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) of Tirzepatide was evaluated.

    Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose

  2. PK: Maximum Concentration of Tirzepatide

    Cmax is the maximum observed concentration of Tirzepatide.

    Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose

  3. PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])

    Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of Tirzepatide was evaluated.

    Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose

08

Results

Posted Mar 23, 2023

Participant flow

Participant flow — Overall Study
MilestoneTirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)
Started148878
Received at least one dose of study drug148878
Completed138878
Not completed10000
Withdrew: Physician decision10000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) of Tirzepatide was evaluated.

Time frame:
Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
Reported as:
Geometric mean · Nanogram*hour per Millilitre (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])
Nanogram*hour per Millilitre (ng*h/mL)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])78400 ± 2481900 ± 3698300 ± 3281200 ± 988500 ± 14
PrimaryPK: Maximum Concentration of Tirzepatide

Cmax is the maximum observed concentration of Tirzepatide.

Time frame:
Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
Reported as:
Geometric mean · Nanogram per Millilitre (ng/mL)
PK: Maximum Concentration of Tirzepatide
Nanogram per Millilitre (ng/mL)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)
PK: Maximum Concentration of Tirzepatide339 ± 21353 ± 42369 ± 36417 ± 11347 ± 30
PrimaryPK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])

Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of Tirzepatide was evaluated.

Time frame:
Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
Reported as:
Geometric mean · Nanogram*hour per Millilitre (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])
Nanogram*hour per Millilitre (ng*h/mL)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)
PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])80500 ± 2584200 ± 3710400 ± 3283000 ± 1093400 ± 12

Adverse events

Collected over Up to 28days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide - Control0/14 (0%)0/14 (0%)1/14 (7.1%)
Tirzepatide - Mild Renal Impairment0/8 (0%)0/8 (0%)4/8 (50%)
Tirzepatide - Moderate Renal Impairment0/8 (0%)0/8 (0%)3/8 (37.5%)
Tirzepatide - Severe Renal Impairment0/7 (0%)0/7 (0%)3/7 (42.9%)
Tirzepatide - End Stage Renal Disease (ESRD)0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventTirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)
ConstipationGastrointestinal disorders0/142/80/80/70/8
VomitingGastrointestinal disorders0/140/80/81/72/8
AnaemiaBlood and lymphatic system disorders0/140/80/81/70/8
DiarrhoeaGastrointestinal disorders0/141/81/81/70/8
HeadacheNervous system disorders1/140/80/81/70/8
Orthostatic hypotensionVascular disorders0/140/80/81/70/8
Abdominal distensionGastrointestinal disorders0/140/81/80/70/8
NauseaGastrointestinal disorders0/141/80/80/71/8
ContusionInjury, poisoning and procedural complications0/140/81/80/70/8
Back painMusculoskeletal and connective tissue disorders0/141/81/80/70/8

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)Total
Mean58.1 ± 7.663.3 ± 6.668.8 ± 14.160.3 ± 9.352.9 ± 7.260.3 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)Total
Female5341215
Male9546630
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)Total
Hispanic or Latino2534014
Not Hispanic or Latino12353831
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)Total
American Indian or Alaska Native000000
Asian002002
Native Hawaiian or Other Pacific Islander000000
Black or African American7231821
White7636022
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)Tirzepatide - ControlTirzepatide - Mild Renal ImpairmentTirzepatide - Moderate Renal ImpairmentTirzepatide - Severe Renal ImpairmentTirzepatide - End Stage Renal Disease (ESRD)Total
United States14887845
09

Study locations

4 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
10

References and documents

Publications

  • Urva S, Quinlan T, Landry J, Martin J, Loghin C. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021 Aug;60(8):1049-1059. doi: 10.1007/s40262-021-01012-2. Epub 2021 Mar 29. PubMed 33778934 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Aug 2019, 16 months.

Results were first posted in Mar 2023, 3 years 7 months after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 29, 2018
StartActual
Mar 30, 2018
Primary completionActual
Aug 19, 2019
CompletionActual
Aug 19, 2019
Results first posted
Mar 23, 2023
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03482024
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 30, 2018
Primary completion
Aug 19, 2019
Completion
Aug 19, 2019
Results posted
Mar 23, 2023
Last update
Mar 23, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion